5393-46-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-nitrobiphenyl-4-yl)acetamide is used as a building block for the synthesis of pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs and medications.
Used in Organic Chemistry:
N-(3-nitrobiphenyl-4-yl)acetamide is used as a building block in organic chemistry. Its versatile structure allows for various chemical reactions and modifications, making it a useful tool for researchers and chemists in the development of new chemical products.
Used in Agrochemical Production:
N-(3-nitrobiphenyl-4-yl)acetamide may have potential applications as an intermediate in the production of agrochemicals. Its unique structure and properties could contribute to the development of new and effective agricultural products.
Used in Dye Production:
N-(3-nitrobiphenyl-4-yl)acetamide may also have potential applications in the production of dyes. Its chemical properties could be utilized to create new and innovative dyes for various industries.

InChI:InChI=1/C14H12N2O3/c1-10(17)15-13-8-7-12(9-14(13)16(18)19)11-5-3-2-4-6-11/h2-9H,1H3,(H,15,17)

Upstream product

• 408508-69-0 N-biphenyl-4-yl-diacetamide 
• 7697-37-2 nitric acid 
• 92-67-1 4-phenylalanine 
• 108-24-7 acetic anhydride 
• 5345-53-9 nitro-p-phenylenediamine N¹,N⁴-diacetate 
• 4075-79-0 4-phenylacetanilide 

Downstream Products

• 68527-70-8 6-phenyl-8-nitroquinoline 
• 38233-82-8 2-methyl-5-phenyl-1⁽³⁾H-benzoimidazole 
• 2113-54-4 N-(biphenyl-3-yl)acetamide 
• 2113-58-8 3-nitro-1,1'-biphenyl 
• 6153-89-5 5-phenyl-1,10-phenanthroline 
• 4085-18-1 4-amino-3-nitrobiphenyl 

Relevant academic research and scientific papers

The Curious Case of a Phenylated Guanidinoquinoline Ligand: Synthesis, Complexes and ATRP Properties of DMEG6phqu

In previous studies, copper halide complexes of the guanidinoquinoline (GUAqu) ligands 1,3-dimethyl-N-(quinolin-8-yl)-imidazolidin-2-imine (DMEGqu) and 1,1,3,3-tetramethyl-2-(quinolin-8-yl)-guanidine (TMGqu) were successfully implemented in atom transfer radical polymerization (ATRP) and could be further enhanced by introduction of alkyl substituents at C6 position of the quinoline backbone. Herein, the ligand DMEG6phqu is presented. The quinoline backbone of this ligand is equipped with a phenyl substituent at C6 position. This study deals with the influence of the phenyl substituent on solubility and molecular structural properties of DMEG6phqu CuI and CuII bromide complexes. In contrast to previously reported systems, the CuIBr complex of DMEG6phqu crystallizes as a trigonal coordinated monochelate complex. However, NMR and UV/Vis spectroscopic experiments indicate that DMEG6phqu forms a bischelate species in solution. The influence of the substituent on the complex redox potential and ATRP equilibrium constant KATRP is discussed. In contrast to expectations, it turned out that copper halide complexes of DMEG6phqu are completely insoluble in the apolar monomer styrene. However, ATRP kinetics were performed in solution and the results are compared to previous studies.

Substituted benzimidazoles

The invention relates to new substituted benzimidazoles of the general formula (I) STR1 in which R1 represents hydrogen, alkyl, alkoxy or optionally substituted aryl, R2 represents hydroxyl, cyano or in each case optionally substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy, alkinyloxy, alkylthio, amino, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, dialkoxyphosphonyl, (hetero)aryl, (hetero)arylcarbonyl, (hetero)aryloxycarbonyl, (hetero)arylcarbonyloxy or (hetero)arylaminocarbonylaminocarbonyloxy, and R3 represents fluoroalkyl, X1, X2, X3 and X4 independently of one another in each case represent hydrogen, halogen, cyano, nitro, in each case optionally substituted alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl or cycloalkyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl or in each case optionally substituted aryl, aryloxy, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, but where at least one of the substituents X1, X2, X3 or X4 represents halogenoalkyl, with the exception of the chloromethyl radical, halogenoalkoxy, halogenoalkylthio, halogenoalkylsulphinyl, halogenoalkylsulphonyl or alkylsulphonyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl, or in each case optionally substituted aryl, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, their preparation and use as pesticides, and intermediates for their preparation.

Benzimidazole compounds

The present patent application discloses compounds having the formula STR1 or a pharmaceutically acceptable salt thereof wherein R 3, R 4, R 6 and R 7 each have the meanings set forth in the specification.The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

Method of treating parastic protozoa with substituted benzimidazoles

The present invention relates to the use of benzimidazoles of the formula (I) STR1 in which X1, X2, X3, X4, R3 and R5 are described herein and these compounds are agents for combatting parasitic protozoa, in particular coccidia.

Benzimidazole useful in the treatment of central nervous system disorders

Compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein, R3 is are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

Reactivity and selectivity of nitrenium ions derived from ester derivatives of carcinogenic N-(4-biphenylyl)hydroxylamine and the corresponding hydroxamic acid

N-Acetyl-N-(sulfonatooxy)-4-aminobiphenyl (1a) and N-(4-biphenylyl)-O-pivaloylhydroxylamine (1c) decompose in 5% CH3CN/H2O, μ = 0.5 M, at 20°C via rate-limiting N-O bond heterolysis to generate the nitrenium ion intermediates 2a and 2b, respectively. Addition of Cl- (≤0.5 M) or N3- (≤0.05 M) causes a marked decrease in the yields of all hydrolysis products derived from 1a and 1c, except the rearrangement products 10a and 11, without any change in the hydrolysis rate constants. At 0.5 M Cl- more than 75% of the trappable hydrolysis products of 1a are replaced by the chloro adduct 7a without any observable change in the hydrolysis rate constant, and at 0.025 M N3- 96% of the trappable hydrolysis products of 1a are replaced by the azide adduct 8a, again, without an observable change in the hydrolysis rate constant. Similar results are obtained for 1c. The nucleophile/solvent selectivity ratios, kcl/ks and kaz/ks, are 7.4 ± 0.3 M-1 and (1.02 ± 0.04) × 103 M-1, respectively, for 2a. For 2b k/cl/ks is 15.7 ± 0.8 M-1 and kaz/ks is (2.9 ± 0.2) × 103 M-1. If kaz is at the diffusion controlled limit of 5 × 109 M-1 s-1, ks for 2a is 4.9 × 106 s-1, and ks for 2b is 1.7 × 106 s-1. Both of these ions are considerably less labile to solvent attack than 1-phenylethyl or cumyl carbocations with a 4-phenyl substituent. Surprisingly, 2a and 2b differ in their reactivity to solvent by only a factor of 3, while the estimated rate constants for their generation from starting materials with identical leaving groups differ by a factor of 106. This phenomenon is similar to the situation previously observed by Richard for 1-aryl2,2,2-trifluoroethyl and 1-arylethyl carbocations and may be due to similar factors. A detailed mechanism for the hydrolysis of 1a and 1c, which is consistent with all available experimental data, is presented. The implications of these results for the mechanisms of chemical carcinogenesis by N-arylhydroxylamine derivatives are discussed.